T1	Participants 40 154	postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer?
T2	Participants 318 386	postmenopausal women with highly endocrine responsive breast cancer.
T3	Participants 464 575	postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer